China’s Generon Starts Clinical Trial of Biologic Anti-Inflammatory Drug

Generon (Shanghai) Corporation has started a clinical trial for the second of its biologic drugs to begin human testing. The anti-inflammatory drug, known as F-652, will enter a Phase I trial in Australia. F-652 is a recombinant protein containing a human interleukin-22 (IL-22) dimer. According to Generon, F-652 is a first-in-class drug candidate, while the company’s other three molecules under development aim for best-in-class status. Generon believes that F-652 will ultimately address unmet medical needs in several inflammatory diseases. More details... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});